Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Unknown 3

Sponsor Class

INDUSTRY 3

Study Type

Observational 2Interventional 1

Sponsor

Conditions

Neoplasms 183Breast Neoplasms 174Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 105Stomach Neoplasms 81Pancreatic Neoplasms 79Lung Neoplasms 79Prostatic Neoplasms 77Melanoma 68Neoplasm Metastasis 67Recurrence 66Leukemia, Myeloid, Acute 66Multiple Myeloma 64Ovarian Neoplasms 62Carcinoma, Hepatocellular 62Lymphoma 61Advanced Solid Tumor 61Advanced Solid Tumors 56Solid Tumor 50Uterine Cervical Neoplasms 48Lymphoma, Non-Hodgkin 48Glioblastoma 44Lymphoma, B-Cell 40Leukemia 39Colonic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Sarcoma 30

Interventions

Nasal Sprays 2Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Breakthrough Cancer Pain × Clear all
NCT04713189 2021-02-02

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain

Lee's Pharmaceutical Limited

Phase 1/2 Unknown
96 enrolled

Breakthrough Cancer Pain

NCT01693328 2014-01-15

Qualipec

Archimedes Development Ltd

Unknown
300 enrolled

Breakthrough Cancer Pain

NCT01698645 2013-07-11

Qualipec

Archimedes Development Ltd

Unknown
150 enrolled

Breakthrough Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡